Repligen Corporation (RGEN)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber.
Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.
The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.
Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
|Industry||Medical Instruments & Supplies|
|CEO||Anthony J. Hunt|
41 Seyon Street, Building 1, Suite 100
Waltham, Massachusetts 02453
|Fiscal Year||January - December|
|Anthony J. Hunt||President, Chief Executive Officer and Director|
|Jon K. Snodgres||Chief Financial Officer|
|James R. Bylund||Chief Operating Officer|
|Christine Gebski||Senior Vice President of Filtration and Chromatography|
|Ralf Kuriyel||Senior Vice President of Research & Development|
|Sondra S. Newman||Global Head of Investor Relations|
|Kimberly Cornwell||Global Head of Legal and General Counsel|
|Stephen Tingley||Vice President and Head of Global Sales|
|Rachel Goodrich||Vice President of Marketing|
|Craig Harrison||Senior Vice President of Process Analytics|
Latest SEC Filings
|May 22, 2023||8-K||Current Report|
|May 2, 2023||10-Q||Quarterly Report|
|May 2, 2023||8-K||Current Report|
|Apr 18, 2023||8-K||Current Report|
|Apr 12, 2023||8-K||Current Report|
|Apr 11, 2023||ARS||Filing|
|Apr 11, 2023||DEF 14A||Other definitive proxy statements|
|Mar 24, 2023||PRE 14A||Other preliminary proxy statements|
|Feb 22, 2023||10-K||Annual Report|
|Feb 22, 2023||8-K||Current Report|